Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Belimumab and Rituximab in Primary Sjögren's Syndrome
NCT02631538Phase 2Completed
- Sponsor
- GSK
- Start
- Feb 2016
- Primary completion
- Jun 2020
- Modality
- Monoclonal Antibodies
- Countries
- 10
01
Overview
A Phase 2 trial of belimumab in primary Sjögren's syndrome, sponsored by GSK. Started Feb 2016; status: completed.
02
Drugs
belimumab
03
Conditions
primary Sjögren's syndrome
Beyond the preview
Go deeper on NCT02631538.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02631538.